Protagenic receives CMC questions from European regulator; expects Q4 2022 trial start

Protagenic Therapeutics, Inc.new

Received CMC (Chemistry, Manufacturing and Controls) questions from a European regulatory authority on August 30, 2022.
Company is addressing the questions and currently expects to commence clinical trials in Q4 2022.
Protagenic is also finalizing its US submission for the same trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.